Benjamin Burnett
Stock Analyst at Wells Fargo
(3.46)
# 947
Out of 5,090 analysts
86
Total ratings
54.84%
Success rate
3.74%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Benjamin Burnett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVDL Avadel Pharmaceuticals | Maintains: Equal-Weight | $20 → $23 | $21.36 | +5.36% | 3 | Nov 20, 2025 | |
| CNTA Centessa Pharmaceuticals | Maintains: Overweight | $30 → $35 | $29.48 | +18.74% | 3 | Nov 13, 2025 | |
| ALKS Alkermes | Maintains: Overweight | $42 → $37 | $29.30 | +26.30% | 3 | Nov 13, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $163 → $157 | $148.41 | +5.79% | 2 | Nov 4, 2025 | |
| FATE Fate Therapeutics | Maintains: Hold | $5 → $3 | $1.11 | +171.49% | 3 | Mar 6, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Hold | $53 → $49 | $58.85 | -16.74% | 6 | Feb 13, 2025 | |
| ACLX Arcellx | Maintains: Buy | $83 → $122 | $68.14 | +79.06% | 5 | Oct 18, 2024 | |
| BEAM Beam Therapeutics | Maintains: Buy | $66 → $69 | $29.01 | +137.85% | 2 | Sep 11, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $63 → $68 | $35.95 | +89.15% | 7 | Sep 10, 2024 | |
| ALLO Allogene Therapeutics | Maintains: Hold | $4.4 → $4.6 | $1.45 | +218.34% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $120 → $58 | $14.19 | +305.21% | 4 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $690 → $780 | $5.04 | +15,391.56% | 2 | Sep 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $16 | $7.56 | +111.64% | 1 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $8 | $5.73 | +39.74% | 1 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $23 | $20.24 | +13.64% | 1 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $73 → $93 | $77.83 | +19.50% | 1 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $44 | $44.69 | -1.54% | 2 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $414 → $423 | $485.21 | -12.82% | 1 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $64 | $78.51 | -18.48% | 5 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $94 | $93.70 | +0.32% | 7 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $4 | $2.24 | +78.97% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $3.76 | +166.31% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $2.22 | +1,026.13% | 11 | Sep 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $330 → $360 | $57.50 | +526.14% | 2 | Jun 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $16 | $0.54 | +2,887.86% | 1 | Jan 6, 2021 |
Avadel Pharmaceuticals
Nov 20, 2025
Maintains: Equal-Weight
Price Target: $20 → $23
Current: $21.36
Upside: +5.36%
Centessa Pharmaceuticals
Nov 13, 2025
Maintains: Overweight
Price Target: $30 → $35
Current: $29.48
Upside: +18.74%
Alkermes
Nov 13, 2025
Maintains: Overweight
Price Target: $42 → $37
Current: $29.30
Upside: +26.30%
Axsome Therapeutics
Nov 4, 2025
Maintains: Overweight
Price Target: $163 → $157
Current: $148.41
Upside: +5.79%
Fate Therapeutics
Mar 6, 2025
Maintains: Hold
Price Target: $5 → $3
Current: $1.11
Upside: +171.49%
CRISPR Therapeutics AG
Feb 13, 2025
Maintains: Hold
Price Target: $53 → $49
Current: $58.85
Upside: -16.74%
Arcellx
Oct 18, 2024
Maintains: Buy
Price Target: $83 → $122
Current: $68.14
Upside: +79.06%
Beam Therapeutics
Sep 11, 2024
Maintains: Buy
Price Target: $66 → $69
Current: $29.01
Upside: +137.85%
IDEAYA Biosciences
Sep 10, 2024
Maintains: Buy
Price Target: $63 → $68
Current: $35.95
Upside: +89.15%
Allogene Therapeutics
May 14, 2024
Maintains: Hold
Price Target: $4.4 → $4.6
Current: $1.45
Upside: +218.34%
Apr 1, 2024
Maintains: Hold
Price Target: $120 → $58
Current: $14.19
Upside: +305.21%
Sep 10, 2021
Maintains: Buy
Price Target: $690 → $780
Current: $5.04
Upside: +15,391.56%
Nov 11, 2025
Maintains: Overweight
Price Target: $18 → $16
Current: $7.56
Upside: +111.64%
Nov 11, 2025
Maintains: Overweight
Price Target: $10 → $8
Current: $5.73
Upside: +39.74%
Nov 11, 2025
Maintains: Overweight
Price Target: $26 → $23
Current: $20.24
Upside: +13.64%
Nov 5, 2025
Maintains: Overweight
Price Target: $73 → $93
Current: $77.83
Upside: +19.50%
Nov 4, 2025
Maintains: Overweight
Price Target: $48 → $44
Current: $44.69
Upside: -1.54%
Oct 30, 2025
Maintains: Equal-Weight
Price Target: $414 → $423
Current: $485.21
Upside: -12.82%
Apr 1, 2025
Maintains: Buy
Price Target: $78 → $64
Current: $78.51
Upside: -18.48%
Jan 24, 2025
Maintains: Buy
Price Target: $90 → $94
Current: $93.70
Upside: +0.32%
Dec 13, 2024
Maintains: Buy
Price Target: $9 → $4
Current: $2.24
Upside: +78.97%
Jun 3, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $3.76
Upside: +166.31%
Sep 15, 2023
Reiterates: Buy
Price Target: $25
Current: $2.22
Upside: +1,026.13%
Jun 28, 2021
Upgrades: Buy
Price Target: $330 → $360
Current: $57.50
Upside: +526.14%
Jan 6, 2021
Initiates: Hold
Price Target: $16
Current: $0.54
Upside: +2,887.86%